Prime Medicine wins arbitration with Beam over AATD therapy PM647

Beam Therapeutics
Prime Medicine, Inc.

Beam Therapeutics

BEAM

0.00

Prime Medicine, Inc.

PRME

0.00
  • Prime Medicine won a binding arbitration with Beam Therapeutics under their 2019 collaboration and license agreement.
  • The tribunal ruled PM647 falls within Prime Medicine’s licensed “Field,” finding no breach tied to its AATD program.
  • No monetary damages were awarded to Beam.
  • Prime Medicine targets an IND and/or CTA filing for PM647 in Q3 2026; initial clinical data expected in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607080800PRIMZONEFULLFEED9758777) on July 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.